NASDAQ:RGNXRegenxbio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Regenxbio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $33.62 -0.68 (-1.98 %) (As of 08/7/2020 11:27 AM ET) Add Compare Share Today's Range$33.11Now: $33.62▼$34.5550-Day Range$33.10MA: $37.06▼$40.2652-Week Range$20.03Now: $33.62▼$54.97Volume2,434 shsAverage Volume299,174 shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/ABeta1.01 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingRegenxbio has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.00, Regenxbio has a potential upside of 74.9% from its current price of $34.30.Amount of Analyst CoverageRegenxbio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesRegenxbio has received 376 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRegenxbio has received 323 “underperform” votes. (Add your “underperform” vote.)Community SentimentRegenxbio has received 53.79% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote “Outperform” if you believe RGNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRegenxbio does not currently pay a dividend.Dividend GrowthRegenxbio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regenxbio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $900,755.00 in company stock.Percentage Held by InsidersOnly 14.10% of the stock of Regenxbio is held by insiders.Percentage Held by Institutions76.68% of the stock of Regenxbio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Regenxbio are expected to grow in the coming year, from ($2.87) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regenxbio is -12.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Regenxbio is -12.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRegenxbio has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RGNX Previous Symbol CUSIPN/A CIK1590877 Webwww.regenxbio.com Phone240-552-8181Debt Debt-to-Equity Ratio0.02 Current Ratio10.64 Quick Ratio10.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$35.23 million Price / Sales35.54 Cash FlowN/A Price / Cash FlowN/A Book Value$12.23 per share Price / Book2.75Profitability EPS (Most Recent Fiscal Year)($3.26) Net Income$-94,730,000.00 Net Margins-197.23% Return on Equity-27.84% Return on Assets-25.51%Miscellaneous Employees192 Outstanding Shares37,240,000Market Cap$1.25 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $33.62 -0.68 (-1.98 %) (As of 08/7/2020 11:27 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RGNX News and Ratings via Email Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Regenxbio (NASDAQ:RGNX) Frequently Asked Questions How has Regenxbio's stock been impacted by COVID-19 (Coronavirus)? Regenxbio's stock was trading at $32.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RGNX shares have increased by 2.2% and is now trading at $33.62. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Regenxbio? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio. When is Regenxbio's next earnings date? Regenxbio is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Regenxbio. How were Regenxbio's earnings last quarter? Regenxbio Inc (NASDAQ:RGNX) issued its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by $0.02. The biotechnology company earned $16.60 million during the quarter, compared to analyst estimates of $22.23 million. Regenxbio had a negative return on equity of 27.84% and a negative net margin of 197.23%. Regenxbio's quarterly revenue was up 110.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.04) EPS. View Regenxbio's earnings history. What price target have analysts set for RGNX? 6 equities research analysts have issued 1-year price targets for Regenxbio's stock. Their forecasts range from $37.00 to $100.00. On average, they expect Regenxbio's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 78.5% from the stock's current price. View analysts' price targets for Regenxbio. Has Regenxbio been receiving favorable news coverage? Media stories about RGNX stock have trended positive on Friday, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regenxbio earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Regenxbio. Who are some of Regenxbio's key competitors? Some companies that are related to Regenxbio include Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA), bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Twist Bioscience (TWST), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Immunovant (IMVT), Editas Medicine (EDIT) and SpringWorks Therapeutics (SWTX). View all competitors. What other stocks do shareholders of Regenxbio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ). Who are Regenxbio's key executives? Regenxbio's management team includes the following people: Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)Dr. Olivier Danos, Chief Scientific Officer (Age 61)Dr. Stephen Yoo, Consultant (Age 41) What is Regenxbio's stock symbol? Regenxbio trades on the NASDAQ under the ticker symbol "RGNX." Who are Regenxbio's major shareholders? Regenxbio's stock is owned by a number of retail and institutional investors. Top institutional investors include Botty Investors LLC (0.81%), UBS Group AG (0.81%), Principal Financial Group Inc. (0.67%), Swiss National Bank (0.19%), P.A.W. Capital Corp (0.19%) and New York State Teachers Retirement System (0.13%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View institutional ownership trends for Regenxbio. Which major investors are selling Regenxbio stock? RGNX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, WINTON GROUP Ltd, Assenagon Asset Management S.A., Hancock Whitney Corp, Texas Permanent School Fund, Arizona State Retirement System, and Liberty One Investment Management LLC. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Patrick J Christmas, and Vittal Vasista. View insider buying and selling activity for Regenxbio. Which major investors are buying Regenxbio stock? RGNX stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp, Essex Investment Management Co. LLC, Mackay Shields LLC, New York State Teachers Retirement System, Principal Financial Group Inc., Swiss National Bank, ProShare Advisors LLC, and New York State Common Retirement Fund. View insider buying and selling activity for Regenxbio. How do I buy shares of Regenxbio? Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Regenxbio's stock price today? One share of RGNX stock can currently be purchased for approximately $33.62. How big of a company is Regenxbio? Regenxbio has a market capitalization of $1.25 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe. What is Regenxbio's official website? The official website for Regenxbio is www.regenxbio.com. How can I contact Regenxbio? Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
